I was going over the last conference call and it sounds like IGEN, in collaboration with a major player, will soon announce a POC machine with a cardiac panel. Maybe tomorrow?
--Jim
Here is the complete quote:
CORPORATE PARTICIPANT: That was a long,long question. So let me say that we have had our priorities in building the company, and the first priority was to win the termination. That is what we spent a tremendous amount of time and effort, and we are just ecstatic about the results yesterday. Of course, of all the things we just said that the clarity it gives us and the right to now go ahead with our business. And that brings us to the second priority which was to create strategic alliances, global strategic alliances with manufacturing companies on the one hand and distribution companies on the other hand. We can't say more about that now because it's just not practical for us to talk about it but we will talk about it as things unfold. But it has been a major priority, we have worked on it, and I think all the shareholders will be delighted with the results as they unfold. And our third priority has been to establish ourselves as the leading supplier of the consumables used in these systems. And I think we'll have more to say that in -- about that in the coming days, but we have said in terms of the biodefense [asset] how well we have been doing and how well our FASTubes have done. We think the FASTubes open up a whole new consumable opportunity in the clinical area as well, and we'll have more to say about that soon.
What is important to realize when we talk to these other companies, especially distribution companies, we have companies that compete with Roche in the marketplace. What was needed to complete those discussions to get things done was to have the clarity that the court has not provided. And now we can move forward in a way and with [-- an a lack of things] that hasn't being possible before because of the cloud and the uncertainties. So a new age has now gone. And I want to thank you. As far as the financing, George has repeatedly said that we feel very comfortable about our financial position.
[ . . . and later . . . ]
CORPORATE PARTICIPANT: Let me just give you some information on a focused activity. It is been demonstrated by people in the marketplace that if not the hardest one of the most exciting areas are the cardiac tests and congestive hearth failure tests in the clinical area and point of care area just to be specific. And we intend with our manufacturing alliance and distribution alliance to be able to penetrate that business to actually expand the market and take market share. We are talking about with a limited number of tests. I'd say the cardiac test of three or four assays to create an opportunity in the hundreds of millions of dollars and do it in real time. I think the speed at which other companies have developed very, very high growth with less then -- well far less attribute than our technology by far. We will come into the market and we will be the dominant player in that market. So just for starters we are talking about potential in real time huge revenue numbers from the demand of dollars. |
